Iparomlimab and Tuvonralimab Injection (QL1706)
2025-SR-348
Phase 2 small_molecule active
Quick answer
Iparomlimab and Tuvonralimab Injection (QL1706) for Hepatocellular Carcinoma is a Phase 2 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Hepatocellular Carcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active